Cargando…

Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease

BACKGROUND: The purpose of this study was to evaluate the effects of caprylic triglyceride (CT) in patients with mild-to-moderate Alzheimer’s disease (AD) in routine clinical practice via review of medical records and caregiver questionnaires. METHODS: Participants were outpatients aged ≥50 years wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Maynard, Steven Douglas, Gelblum, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810439/
https://www.ncbi.nlm.nih.gov/pubmed/24187497
http://dx.doi.org/10.2147/NDT.S52331
_version_ 1782288787755237376
author Maynard, Steven Douglas
Gelblum, Jeff
author_facet Maynard, Steven Douglas
Gelblum, Jeff
author_sort Maynard, Steven Douglas
collection PubMed
description BACKGROUND: The purpose of this study was to evaluate the effects of caprylic triglyceride (CT) in patients with mild-to-moderate Alzheimer’s disease (AD) in routine clinical practice via review of medical records and caregiver questionnaires. METHODS: Participants were outpatients aged ≥50 years with a diagnosis of probable mild-to-moderate AD who had received CT for ≥6 months. The primary outcome was change from baseline in the patient’s condition as rated by the treating physician using a physician’s overall assessment. RESULTS: A total of 55 patients were included. The physician’s overall assessment indicated that ~80% of patients who had CT added to ongoing pharmacotherapy were stable or improved. Mini-Mental State Examination scores also remained stable over 15 months of therapy (20.6 ± 3.0 at baseline and 20.1 ± 5.6 at follow-up, P = 0.5233, n = 27). Caregiver assessments indicated that most patients were stable or improved with respect to memory and ability to carry out activities of daily living. The most frequent adverse events with CT involved the gastrointestinal system. CONCLUSION: Results from this chart review indicate that addition of CT to pharmacotherapy was associated with stable disease or improvement over a follow-up period of 18.8 months.
format Online
Article
Text
id pubmed-3810439
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38104392013-11-01 Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease Maynard, Steven Douglas Gelblum, Jeff Neuropsychiatr Dis Treat Original Research BACKGROUND: The purpose of this study was to evaluate the effects of caprylic triglyceride (CT) in patients with mild-to-moderate Alzheimer’s disease (AD) in routine clinical practice via review of medical records and caregiver questionnaires. METHODS: Participants were outpatients aged ≥50 years with a diagnosis of probable mild-to-moderate AD who had received CT for ≥6 months. The primary outcome was change from baseline in the patient’s condition as rated by the treating physician using a physician’s overall assessment. RESULTS: A total of 55 patients were included. The physician’s overall assessment indicated that ~80% of patients who had CT added to ongoing pharmacotherapy were stable or improved. Mini-Mental State Examination scores also remained stable over 15 months of therapy (20.6 ± 3.0 at baseline and 20.1 ± 5.6 at follow-up, P = 0.5233, n = 27). Caregiver assessments indicated that most patients were stable or improved with respect to memory and ability to carry out activities of daily living. The most frequent adverse events with CT involved the gastrointestinal system. CONCLUSION: Results from this chart review indicate that addition of CT to pharmacotherapy was associated with stable disease or improvement over a follow-up period of 18.8 months. Dove Medical Press 2013 2013-10-23 /pmc/articles/PMC3810439/ /pubmed/24187497 http://dx.doi.org/10.2147/NDT.S52331 Text en © 2013 Maynard and Gelblum. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Maynard, Steven Douglas
Gelblum, Jeff
Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
title Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
title_full Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
title_fullStr Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
title_full_unstemmed Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
title_short Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
title_sort retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810439/
https://www.ncbi.nlm.nih.gov/pubmed/24187497
http://dx.doi.org/10.2147/NDT.S52331
work_keys_str_mv AT maynardstevendouglas retrospectivecohortstudyoftheefficacyofcaprylictriglycerideinpatientswithmildtomoderatealzheimersdisease
AT gelblumjeff retrospectivecohortstudyoftheefficacyofcaprylictriglycerideinpatientswithmildtomoderatealzheimersdisease